Ren et al., 2007 - Google Patents
Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile …Ren et al., 2007
- Document ID
- 7429922721058372987
- Author
- Ren J
- Nichols C
- Chamberlain P
- Weaver K
- Short S
- Chan J
- Kleim J
- Stammers D
- Publication year
- Publication venue
- Journal of medicinal chemistry
External Links
Snippet
The selection of drug resistant viruses is a major problem in efforts to combat HIV and AIDS, hence, new compounds are required. We report crystal structures of wild-type and mutant HIV-1 RT with bound non-nucleoside (NNRTI) GW420867X, aimed at investigating the basis …
- 230000002401 inhibitory effect 0 title abstract description 341
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulfur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ren et al. | Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptases | |
| Himmel et al. | Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains | |
| Ren et al. | Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors | |
| Hopkins et al. | Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1. | |
| Ren et al. | Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives | |
| Himmel et al. | HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site | |
| Lansdon et al. | Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design | |
| Greenwald et al. | The mobility of an HIV-1 integrase active site loop is correlated with catalytic activity | |
| Rizzo et al. | Estimation of binding affinities for HEPT and nevirapine analogues with HIV-1 reverse transcriptase via Monte Carlo simulations | |
| Giffin et al. | A copper (I)-catalyzed 1, 2, 3-triazole azide− alkyne click compound is a potent inhibitor of a multidrug-resistant HIV-1 protease variant | |
| Ding et al. | Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R 95845 at 2.8 Å resolution | |
| Hopkins et al. | Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants | |
| Das et al. | Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket | |
| Arion et al. | Phenotypic mechanism of HIV-1 resistance to 3 ‘-Azido-3 ‘-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral Reverse Transcriptase | |
| Chung et al. | Synthesis, activity, and structural analysis of novel α-hydroxytropolone inhibitors of human immunodeficiency virus reverse transcriptase-associated ribonuclease H | |
| Hopkins et al. | Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors | |
| Deng et al. | Dynamic pharmacophore model optimization: identification of novel HIV-1 integrase inhibitors | |
| Sluis-Cremer et al. | Human Immunodeficiency Virus Type 1 Reverse Transcriptase Dimer Destabilization by 1-{Spiro [4 ‘‘-amino-2 ‘‘, 2 ‘‘-dioxo-1 ‘‘, 2 ‘‘-oxathiole-5 ‘‘, 3 ‘-[2 ‘, 5 ‘-bis-O-(tert-butyldimethylsilyl)-β-d-ribofuranosyl]]}-3-ethylthymine | |
| Hassam et al. | Novel cyclopropyl-indole derivatives as HIV non-nucleoside reverse transcriptase inhibitors | |
| Kang et al. | 2, 4, 5-trisubstituted pyrimidines as potent HIV-1 NNRTIs: rational design, synthesis, activity evaluation, and crystallographic studies | |
| Ragno et al. | HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies | |
| Rodríguez-Barrios et al. | The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations | |
| Frey et al. | Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants | |
| Ren et al. | Structural insights into mechanisms of non‐nucleoside drug resistance for HIV‐1 reverse transcriptases mutated at codons 101 or 138 | |
| Piscitelli et al. | Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus |